CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range - PubMed (original) (raw)
Comparative Study
. 1995 Dec 1;254(3):392-403.
doi: 10.1006/jmbi.1995.0626.
Affiliations
- PMID: 7490758
- DOI: 10.1006/jmbi.1995.0626
Comparative Study
CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range
W P Yang et al. J Mol Biol. 1995.
Abstract
We describe the investigation of methodologies for the creation of very high affinity human antibodies. The high affinity human antibody b4/12 was optimized for its affinity to the human envelope glycoprotein gp120 of human immunodeficiency virus type 1 (HIV-1). Five libraries of b4/12 were constructed by saturation mutagenesis of complementarity-determining regions (CDRs). Libraries of antibody Fab fragments were displayed on the surface of filamentous phage and selected in vitro for binding to immobilized gp120. Sequential and parallel optimization strategies of CDRs were examined. The sequential CDR walking strategy consistently yielded b4/12 variants of improved affinity in each of the four different optimization sequences examined. This resulted in a 96-fold improvement in affinity. Additivity effects in the antibody combining site were explored by combining independently optimized CDRs in the parallel optimization strategy. Six variants containing optimized CDRs were constructed. Improvement of affinity based on additivity effects proved to be unpredictable but did lead to a modest improvement in affinity. Indeed, only one of the six combinations demonstrated additivity. The highest affinity Fab prepared using this strategy was improved 420-fold in affinity. The affinity of this Fab was 15 pM as compared to 6.3 nM for b4/12. Examination of the kinetics of Fab binding to gp120 revealed that improvements in affinity were dominated by a slowing of the off-rate of the Fab. The methodology presented here provides a route for the improvement of the affinities of antibodies typical of tertiary immune responses into the picomolar range. Such improvements may have profound effects on the utility of antibodies as therapeutic and prophylactic agents.
Similar articles
- Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection.
Torán JL, Sánchez-Pulido L, Kremer L, del Real G, Valencia A, Martínez-A C. Torán JL, et al. Eur J Immunol. 2001 Jan;31(1):128-37. doi: 10.1002/1521-4141(200101)31:1<128::aid-immu128>3.0.co;2-t. Eur J Immunol. 2001. PMID: 11169446 - Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. Calarese DA, et al. Science. 2003 Jun 27;300(5628):2065-71. doi: 10.1126/science.1083182. Science. 2003. PMID: 12829775 - Selection and evolution of high-affinity human anti-viral antibodies.
Barbas CF 3rd, Burton DR. Barbas CF 3rd, et al. Trends Biotechnol. 1996 Jul;14(7):230-4. doi: 10.1016/0167-7799(96)10029-9. Trends Biotechnol. 1996. PMID: 8771795 Review. - Antibodies against HIV-1 from phage display libraries: mapping of an immune response and progress towards antiviral immunotherapy.
Parren PW, Burton DR. Parren PW, et al. Chem Immunol. 1997;65:18-56. doi: 10.1159/000319346. Chem Immunol. 1997. PMID: 9018871 Review. No abstract available.
Cited by
- BAT6026, a novel anti-OX40 antibody with enhanced antibody dependent cellular cytotoxicity effect for cancer immunotherapy.
Liang S, Zheng D, Liu X, Mei X, Zhou C, Xiao C, Qin C, Yue H, Lin J, Liu C, Li S, Yu JC. Liang S, et al. Front Oncol. 2023 Jul 28;13:1211759. doi: 10.3389/fonc.2023.1211759. eCollection 2023. Front Oncol. 2023. PMID: 37576888 Free PMC article. - Arginine cluster introduction on framework region in anti-lysozyme antibody improved association rate constant by changing conformational diversity of CDR loops.
Maeta S, Nakakido M, Matsuura H, Sakai N, Hirata K, Kuroda D, Fukunaga A, Tsumoto K. Maeta S, et al. Protein Sci. 2023 Sep;32(9):e4745. doi: 10.1002/pro.4745. Protein Sci. 2023. PMID: 37550885 Free PMC article. - Protein engineering via sequence-performance mapping.
McConnell A, Hackel BJ. McConnell A, et al. Cell Syst. 2023 Aug 16;14(8):656-666. doi: 10.1016/j.cels.2023.06.009. Epub 2023 Jul 25. Cell Syst. 2023. PMID: 37494931 Free PMC article. Review. - Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5.
Entzminger KC, Fleming JK, Entzminger PD, Espinosa LY, Samadi A, Hiramoto Y, Okumura SCJ, Maruyama T. Entzminger KC, et al. Antib Ther. 2023 Apr 13;6(2):108-118. doi: 10.1093/abt/tbad006. eCollection 2023 Apr. Antib Ther. 2023. PMID: 37324547 Free PMC article. - Docking guided phase display to develop fusion protein with novel scFv and alkaline phosphatase for one-step ELISA salbutamol detection.
Hu S, Yang G, Chen Z, Li Q, Liu B, Liu M, Zhang D, Chang S, Kong R. Hu S, et al. Front Microbiol. 2023 May 12;14:1190793. doi: 10.3389/fmicb.2023.1190793. eCollection 2023. Front Microbiol. 2023. PMID: 37250048 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources